WO2006073311A3 - Treatment of ibd - Google Patents

Treatment of ibd Download PDF

Info

Publication number
WO2006073311A3
WO2006073311A3 PCT/NO2006/000002 NO2006000002W WO2006073311A3 WO 2006073311 A3 WO2006073311 A3 WO 2006073311A3 NO 2006000002 W NO2006000002 W NO 2006000002W WO 2006073311 A3 WO2006073311 A3 WO 2006073311A3
Authority
WO
WIPO (PCT)
Prior art keywords
ibd
treatment
salmonella
prevention
useful
Prior art date
Application number
PCT/NO2006/000002
Other languages
French (fr)
Other versions
WO2006073311A2 (en
Inventor
Arnold Berstad
Gunnar Nysaeter
Original Assignee
Innovest As
Arnold Berstad
Gunnar Nysaeter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovest As, Arnold Berstad, Gunnar Nysaeter filed Critical Innovest As
Publication of WO2006073311A2 publication Critical patent/WO2006073311A2/en
Publication of WO2006073311A3 publication Critical patent/WO2006073311A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a pharmaceutical composition comprising Salmonella or Vibrio cholerae useful for the treatment or prevention of inflammatory bowel disease (IBD).
PCT/NO2006/000002 2005-01-04 2006-01-04 Treatment of ibd WO2006073311A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20050044 2005-01-04
NO20050044A NO20050044L (en) 2005-01-04 2005-01-04 Preparation for the treatment of Colitis ulcerosa & Chrohn's disease

Publications (2)

Publication Number Publication Date
WO2006073311A2 WO2006073311A2 (en) 2006-07-13
WO2006073311A3 true WO2006073311A3 (en) 2006-11-09

Family

ID=35209736

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2006/000002 WO2006073311A2 (en) 2005-01-04 2006-01-04 Treatment of ibd

Country Status (2)

Country Link
NO (1) NO20050044L (en)
WO (1) WO2006073311A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022117823A1 (en) * 2020-12-04 2022-06-09 Valneva Se Methods and compositions for preventing and/or treating autoimmune diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728380A (en) * 1991-04-08 1998-03-17 Unilever Patent Holdings B.V. Priobiotic containing enterococcus faecium strain NCIMB 40371
EP0965347A2 (en) * 1998-06-17 1999-12-22 MED Pharma Service GmbH Use of viable anaerobic bacteria for the preparation of a medicament for inhibiting the growth of sulphate reducing bacteria
US20040067223A1 (en) * 2002-10-06 2004-04-08 The Bio Balance Corporation Probiotic compositions for the treatment of inflammatory bowel disease
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2005058355A1 (en) * 2003-12-11 2005-06-30 Creatogen Laboratories Gmbh Immune stimulation by administration of bacteria

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728380A (en) * 1991-04-08 1998-03-17 Unilever Patent Holdings B.V. Priobiotic containing enterococcus faecium strain NCIMB 40371
EP0965347A2 (en) * 1998-06-17 1999-12-22 MED Pharma Service GmbH Use of viable anaerobic bacteria for the preparation of a medicament for inhibiting the growth of sulphate reducing bacteria
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
US20040067223A1 (en) * 2002-10-06 2004-04-08 The Bio Balance Corporation Probiotic compositions for the treatment of inflammatory bowel disease
WO2005058355A1 (en) * 2003-12-11 2005-06-30 Creatogen Laboratories Gmbh Immune stimulation by administration of bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YU YIMIN ET AL: "TLR5 activation and T-cells are required for generating flagellin-specific immunoglobulin", GASTROENTEROLOGY, vol. 126, no. 4, Suppl. 2, April 2004 (2004-04-01), & DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, pages A127, XP008063046, ISSN: 0016-5085 *

Also Published As

Publication number Publication date
NO20050044D0 (en) 2005-01-04
WO2006073311A2 (en) 2006-07-13
NO20050044L (en) 2006-07-05

Similar Documents

Publication Publication Date Title
WO2007017423A3 (en) Pharmaceutical composition comprising a dpp-iv inhibitor
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2008013838A3 (en) Pyridizinone derivatives
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2006131322A3 (en) Use op brivaracetam for the treatment of diseases characterized by progressive myoclonic epilepsy
WO2007052023A3 (en) Novel compounds
WO2007036363A3 (en) Compositions containing butyric acid ester of carbohydrates and carbohydrate polyols
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007139871A3 (en) Methods and materials for making simvastatin and related compounds
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2007027651A3 (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
WO2008059370A8 (en) Substituted bicyclocarboxyamide compounds
WO2006131836A3 (en) Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2007016029A3 (en) Diazepinoquinolines, synthesis thereof, and intermediates thereto
WO2007118873A3 (en) Polymorphs of atorvastatin sodium and magnesium salts
WO2006105482A3 (en) Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2008033935A3 (en) Vinorelbine derivatives
WO2007115287A3 (en) Combination of organic compounds
WO2006073311A3 (en) Treatment of ibd
WO2007080507A3 (en) Processes for the preparation of azithromycin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06701200

Country of ref document: EP

Kind code of ref document: A2